Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Similar articles for PubMed (Select 9678125)

1.

A delayed starting schedule of oral contraception: the effect on the incidence of breakthrough bleeding and compliance in women.

Yeshaya A, Orvieto R, Kauschansky A, Dicker D, Dekel A, Bar-Hava I, Ben-Rafael Z.

Eur J Contracept Reprod Health Care. 1996 Sep;1(3):263-5.

PMID:
9678125
2.

Toward a new concept of "natural balance" in oral estroprogestin contraception.

Chabbert-Buffet N, Gerris J, Jamin C, Lello S, Lete I, Lobo P, Nappi RE, Pintiaux A.

Gynecol Endocrinol. 2013 Oct;29(10):891-6. doi: 10.3109/09513590.2013.824963. Epub 2013 Aug 9. Review.

PMID:
23931030
3.

Types of combined oral contraceptives used by US women.

Creinin MD.

Contraception. 2013 Jul;88(1):192-3. doi: 10.1016/j.contraception.2012.12.015. Epub 2013 Jan 14. No abstract available.

PMID:
23410715
4.

Response to letter to the editor.

Hall KS, Trussell J.

Contraception. 2013 Jul;88(1):193. doi: 10.1016/j.contraception.2012.12.014. Epub 2013 Jan 10. No abstract available.

PMID:
23375355
5.

Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.

Jensen JT, Garie SG, Trummer D, Elliesen J.

Contraception. 2012 Aug;86(2):110-8. doi: 10.1016/j.contraception.2011.12.009. Epub 2012 Jan 26.

PMID:
22281416
6.

Implications of cycle length immediately after discontinuation of combined oral contraceptives on use of the Standard Days Method.

Arévalo M, Sinai I, Olivotti B, Bahamondes L.

Int J Gynaecol Obstet. 2010 Oct;111(1):78-81. doi: 10.1016/j.ijgo.2010.05.017. Epub 2010 Jul 21.

PMID:
20650457
7.

Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.

Richman S.

Obstet Gynecol. 2010 Apr;115(4):866-7; author reply 867-8. doi: 10.1097/AOG.0b013e3181d70144. No abstract available.

PMID:
20308851
8.

Activation of NF-kappaB and COX-2 expression is associated with breakthrough bleeding in patients using oral contraceptives in extended regimens.

Maia H Jr, Casoy J, Correia T, Athayde C, Valente J, Coutinho EM.

Gynecol Endocrinol. 2010 Apr;26(4):265-9. doi: 10.1080/09513590903247832.

PMID:
19757243
9.

Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate.

Rible RD, Taylor D, Wilson ML, Stanczyk FZ, Mishell DR Jr.

Contraception. 2009 Mar;79(3):182-8. doi: 10.1016/j.contraception.2008.10.005. Epub 2008 Nov 17.

PMID:
19185670
10.

Continuous oral contraception. Strategies for managing breakthrough bleeding.

Freeman SB.

Adv Nurse Pract. 2008 Aug;16(8):36-8. Review. No abstract available.

PMID:
19181174
11.

Extended- and continuous-cycle oral contraceptives.

Shrader SP, Dickerson LM.

Pharmacotherapy. 2008 Aug;28(8):1033-40. doi: 10.1592/phco.28.8.1033. Review.

PMID:
18657019
12.

Effect of two low-dose gestodene containing monophasic oral contraceptives on hemostasis in Bulgarian women.

Uchikova E, Pehlivanov B.

Expert Opin Pharmacother. 2008 Aug;9(11):1839-44. doi: 10.1517/14656566.9.11.1839 .

PMID:
18627323
13.

Continuous-use ethinylestradiol/levonorgestrel 20microg/90microg: as an oral contraceptive.

Wagstaff AJ.

Drugs. 2007;67(16):2473-7; discussion 2478-9. Review.

PMID:
17983260
14.
15.
16.

Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.

Coffee AL, Sulak PJ, Kuehl TJ.

Contraception. 2007 Jun;75(6):444-9. Epub 2007 Mar 23.

PMID:
17519150
17.
18.

Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.

Ahrendt HJ, Nisand I, Bastianelli C, Gómez MA, Gemzell-Danielsson K, Urdl W, Karskov B, Oeyen L, Bitzer J, Page G, Milsom I.

Contraception. 2006 Dec;74(6):451-7. Epub 2006 Sep 27.

PMID:
17157101
19.

Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.

Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle ME, Isaia CF, Petracco A, Peixoto FC, Camargos AF.

Contraception. 2006 Dec;74(6):446-50. Epub 2006 Oct 19.

PMID:
17157100
20.

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.

Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD.

Contraception. 2006 Dec;74(6):439-45. Epub 2006 Sep 18.

PMID:
17157099
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk